Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

NGNE

Neurogene Inc

May 17 • 04:00PM ET

33.31

Dollar change -0.41
Percentage change -1.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS AVSC HELX DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.65	Insider Own	10.43%	Shs Outstand	12.82M	Perf Week	2.49%
Market Cap	432.36M	Forward P/E	-	EPS next Y	-4.07	Insider Trans	0.00%	Shs Float	11.63M	Perf Month	5.48%
Income	-39.03M	PEG	-	EPS next Q	-1.06	Inst Own	83.69%	Short Float	8.74%	Perf Quarter	13.07%
Sales	0.00M	P/S	-	EPS this Y	-241.77%	Inst Trans	-32.38%	Short Ratio	7.33	Perf Half Y	141.38%
Book/sh	13.28	P/B	2.51	EPS next Y	1.97%	ROA	-26.57%	Short Interest	1.02M	Perf Year	91.46%
Cash/sh	13.06	P/C	2.55	EPS next 5Y	25.10%	ROE	-30.96%	52W Range	12.20 - 53.00	Perf YTD	71.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-21.39%	52W High	-37.15%	Beta	1.36
Dividend TTM	-	Quick Ratio	14.74	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	173.03%	ATR (14)	2.54
Dividend Ex-Date	-	Current Ratio	14.74	EPS Y/Y TTM	-143.04%	Oper. Margin	0.00%	RSI (14)	47.22	Volatility	7.89% 7.23%
Employees	91	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	50.25
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-290.56%	Payout	-	Rel Volume	0.36	Prev Close	33.72
Sales Surprise	-	EPS Surprise	3.29%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	138.64K	Price	33.31
SMA20	2.36%	SMA50	-11.85%	SMA200	40.09%	Trades		Volume	49,599	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:14PM	Loading…
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire)
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.

NGNE

Neurogene Inc

Upgrade your FINVIZ experience